Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
German Treatment Optimization Study for Children with De Novo and Relapsed Langerhans Cell Histiocytosis as Part of International LCH-IV
2016-003568-38Phase 3Completed
- Sponsor
- Goethe University Frankfurt
- Start
- Oct 2016
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of prednisone, vinblastine, mercaptopurine, indomethacin and methotrexate in Langerhans cell histiocytosis (LCH) (4 arms), sponsored by Goethe University Frankfurt. Primary endpoint: Reactivation-free survival. Started Oct 2016; status: completed.
02
Drugs
prednisonevinblastinemercaptopurineindomethacinmethotrexate
03
Conditions
Langerhans cell histiocytosis (LCH)
Beyond the preview
Go deeper on 2016-003568-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003568-38.